Literature DB >> 15351427

Expanding the phenotype of potassium channelopathy: severe neuromyotonia and skeletal deformities without prominent Episodic Ataxia.

M Kinali1, H Jungbluth, L H Eunson, C A Sewry, A Y Manzur, E Mercuri, M G Hanna, F Muntoni.   

Abstract

We report an unusual family in which the same point mutation in the voltage-gated potassium channel gene KCNA1 resulted in markedly different clinical phenotypes. The propositus presented in infancy with marked muscle stiffness, motor developmental delay, short stature, skeletal deformities, muscle hypertrophy and muscle rippling on percussion. He did not experience episodic ataxia. His mother presented some years later with typical features of Episodic Ataxia type 1 (EA1), with episodes of ataxia lasting a few minutes provoked by exercise. On examination she had myokymia, joint contractures and mild skeletal deformities. A heterozygous point mutation in the voltage-gated K(+) channel (KCNA1) gene (ACG-AGG, Thr226Arg) was found in both. We conclude that mutations in the potassium channel gene (KCNA1) can cause severe neuromyotonia resulting in marked skeletal deformities even if episodic ataxia is not prominent.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15351427     DOI: 10.1016/j.nmd.2004.06.007

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  23 in total

1.  Clinical heterogeneity associated with KCNA1 mutations include cataplexy and nonataxic presentations.

Authors:  Catherine A Brownstein; Alan H Beggs; Lance Rodan; Jiahai Shi; Meghan C Towne; Renee Pelletier; Siqi Cao; Paul A Rosenberg; David K Urion; Jonathan Picker; Wen-Hann Tan; Pankaj B Agrawal
Journal:  Neurogenetics       Date:  2015-09-22       Impact factor: 2.660

2.  Chronic neuromyotonia as a phenotypic variation associated with a new mutation in the KCNA1 gene.

Authors:  A Poujois; J-Ch Antoine; A Combes; R L Touraine
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

3.  A de novo KCNA1 Mutation in a Patient with Tetany and Hypomagnesemia.

Authors:  Jenny van der Wijst; Martin Konrad; Sjoerd A J Verkaart; Marcin Tkaczyk; Femke Latta; Janine Altmüller; Holger Thiele; Bodo Beck; Karl Peter Schlingmann; Jeroen H F de Baaij
Journal:  Nephron       Date:  2018-05-23       Impact factor: 2.847

4.  Genetic ablation or pharmacological inhibition of Kv1.1 potassium channel subunits impairs atrial repolarization in mice.

Authors:  Man Si; Krystle Trosclair; Kathryn A Hamilton; Edward Glasscock
Journal:  Am J Physiol Cell Physiol       Date:  2018-11-14       Impact factor: 4.249

5.  Scn2a deletion improves survival and brain-heart dynamics in the Kcna1-null mouse model of sudden unexpected death in epilepsy (SUDEP).

Authors:  Vikas Mishra; Bharat K Karumuri; Nicole M Gautier; Rui Liu; Timothy N Hutson; Stephanie L Vanhoof-Villalba; Ioannis Vlachos; Leonidas Iasemidis; Edward Glasscock
Journal:  Hum Mol Genet       Date:  2017-06-01       Impact factor: 6.150

6.  Functional analysis of a novel potassium channel (KCNA1) mutation in hereditary myokymia.

Authors:  Haijun Chen; Christian von Hehn; Leonard K Kaczmarek; Laura R Ment; Barbara R Pober; Fuki M Hisama
Journal:  Neurogenetics       Date:  2006-11-29       Impact factor: 2.660

7.  Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels.

Authors:  Richard G Webster; Keith L Brain; Richard H Wilson; Jean L Grem; Angela Vincent
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

8.  Episodic ataxia type 1 mutations differentially affect neuronal excitability and transmitter release.

Authors:  Joost H Heeroma; Christian Henneberger; Sanjeev Rajakulendran; Michael G Hanna; Stephanie Schorge; Dimitri M Kullmann
Journal:  Dis Model Mech       Date:  2009-09-24       Impact factor: 5.758

Review 9.  Treatment of neuromuscular channelopathies: current concepts and future prospects.

Authors:  James C Cleland; Robert C Griggs
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

10.  Isoform-Selective KCNA1 Potassium Channel Openers Built from Glycine.

Authors:  Rían W Manville; Geoffrey W Abbott
Journal:  J Pharmacol Exp Ther       Date:  2020-03-26       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.